Company

Spark BioPharma, Inc.

Spark BioPharma develops drug screening and target identification technology for anti-cancer drug candidates.

About

Founded in 2016 and based in Seoul, Spark BioPharma develops technology for screening drugs and identifying targets for anti-cancer candidates. In April 2022, it raised KRW 25 billion in Series C funding from Company K Partners, IMM Investment, KB Investment, KTB Network, DT&Investment, Kiwoom Investment, Medytox Venture Investment, Shinhan Venture Investment, Time Folio Asset Management, and We Venture Partners.

6Funding rounds

18Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in